FDA Slowdown Threatens AZN's SERD Lead as Roche Advances
FDA just pumped the brakes hard on AZN's camizestrant. While the SERD track is crowded and Roche is picking up speed, AZN's innovation may be derailed by regulatory conservatism: https://t.co/9eroTXv5dc https://t.co/rOJwh9iMCz
Northwestern Chemist Launches Science-Driven Biotech Blog
New biotech blog by a Northwestern medicinal chemist -- debut post is a well-written, science-focused take on $CCCC. Check it out: https://t.co/4Pc5wUUKlO
Biotech Liquidation Opportunities: ENDI, FNCH, LQDA Outlook
Please find Arquitos Capital's Q1 2026 letter below. I discuss opportunities in liquidating biotechs, $ENDI $FNCH and the range of potential outcomes for $LQDA. https://t.co/LJCczZ04W6
Exercise Proven to Reduce Biological (Epigenetic) Age
What is the most established intervention linked to lower biological (epigenetic) age? Exercise A new systematic review @LancetLongevity of 44 studies, >145,000 participants https://t.co/agmAazwDxs
Gene Editing Swaps Whole Genes, Fixes 1,000 Mutations
A new genome editing technique enables efficient replacement of entire genes, allowing correction of up to 1,000 mutations simultaneously by inserting large DNA segments without causing toxic double-strand breaks. genetherapy
Vaccines May Reduce Alzheimer Risk and Slow Aging
I'm getting two vaccines next week: Tdap and shingles. The Tdap because Kate's family has a newborn and we're visiting. Shingles for the potential longevity benefits. Data we're looking at: 1. Lower Alzheimer risk with vaccination in 1.6 million people,...
CCDC6‑RET Fusion Recycles ADP, Drives Rapid Tumor Activation
The fusion protein CCDC6-RET, implicated in lung and thyroid cancers, can self-activate rapidly and uniquely reuse ADP as an energy source, offering new insight into tumor adaptability and potential therapeutic strategies. cancerbiology
FDA Proposes AI-Driven Real-Time Trials, Ending Phase Gaps
No more Phase 1, 2, or 3 in clinical trials? The FDA is proposing using AI to get trial data in real-time from EHRs and giving trial design feedback based on what it sees. No more batch processing could eliminate the wait...
Small Stem Cell Edit Generates Persistent Antibody Protection
Researchers showed that editing a small number of blood stem cells can reprogram the immune system to continuously produce therapeutic proteins, including powerful antibodies that are normally hard to generate. In mice, this approach created long-lasting, boostable protection against infections...
Semaglutide Restores Lacrimal Gland, Relieves Age‑Related Dry Eye
Semaglutide alleviates age-related dry eye disease by restoring lacrimal gland structure and function https://t.co/EDvPtdeiqg https://t.co/Kpku8SHEOH
Biotech Momentum Stalls as XBI Dips Below January Highs
Still tough to hold momentum in biotech. $XBI slipping back below its January highs. Lets see if the weekly close can save it. https://t.co/zbU6jtuq35
Polygenic Scores Predict Cardiovascular Risk, but Remain Unused Clinically
Polygenic risk scores for 8 cardiovascular traits in both @MassGenBrigham and @AllofUsResearch—superimposable— strongly indicate risk. Yet still not implemented in clinical practice https://t.co/DwWpwXknbJ
Ageing Forms Gene Network Linking Diseases via Two Pathways
Ageing isn't one disease, it's a network. Excited to share our latest study exploring the genetic links between ageing and age-related diseases 🧬 We show how shared pleiotropic genes connect disease clusters, revealing two distinct genetic architectures: one driven by ageing-related...
Late‑Stage Drug Development Trends: Phase III, AI, Global Partnerships
LOOKING forward to tomorrow's webinar on late-stage drug development trends with Susan Galbraith (AstraZeneca), Levi Garraway (Roche) and Ken Getz (Tufts). We'll be discussing the fundamentals of Phase III, with thoughts on efficiencies, interplay with biotech partners, China, AI, and...
FDA Pilots Real-Time Trials as AbbVie Eyes KRAS Biotech
FDA tests out ‘real-time’ clinical trials; AbbVie closes in on a KRAS biotech https://t.co/diuieVTJ3g $ABBV $LLY $GSK $IONS $PFE #biotech
FDA to Relax Peptide Rules After High‑profile Endorsement
FDA moves toward easing restrictions on certain peptides The agency’s decision to hold an advisory committee meeting on the topic comes after HHS Secretary Robert F. Kennedy Jr. told podcaster Joe Rogan he’s a “big fan” of peptides. https://t.co/wynhLuBUPE https://t.co/y9dgG0xWAq
Quintuple Receptor Agonist Outperforms Tirzepatide in Trials
New @Nature A quintuple [GLP-1 + 4 other] receptor agonist drug that exceeds effects of the dual receptor (GLP-1 and GIP, tirzepatide) in the experimental model vs diabetes and obesity (in case you thought a dual receptor was max effect, as...
Tomorrow's Dual AZN ODAC: Serena-6 AM, Truqap-281
Reminder that the dual $AZN ODAC takes place tomorrow. Camizestrant Serena-6 trial being debated in the morning, then Truqap Capitello-281 in the afternoon. Youtube link -> https://t.co/RDcvhRqVWR
Skin Nerve Fibers Slow Melanoma Growth, Challenging Cancer Neuroscience
A twist in cancer neuroscience with many studies showing hijacking of neurons to promote cancer—melanoma growth slowed by nerve fibers in skin https://t.co/9OWEAhJPOb https://t.co/XGSdYYPqk8
SYRE Jumps to $8B After Breakthrough UC Trial
$SYRE pushing $8 billion cap currently on a major $XBI red day following their open label a4b7 data proving that a4b7 continues to work. Valuation was ~$3B at the start of the year. Must’ve been a massive surprise that their...
Never Blindly Trust Data, Even From Trusted Sources
1/ Bioinformaticians, I’ll say it loud: Never blindly trust the data you're given. Not from collaborators. Not from vendors. Not even from “reliable” sources. Here’s why: https://t.co/zXhgzqyISi
US Firm Implants Brain Device in China, Rare Cooperation
"A US company has tested a brain implant in a Chinese patient in Shanghai, a rare sign of cooperation as the two countries compete to develop the most advanced neurotechnology." https://t.co/4xEs7DZTpk
FDA Halts Manual Trial Data Entry, AI Opportunity Ignored
The FDA Finally Stopped Re-Typing Clinical Trial Data. That's the AI Story Nobody Is Writing. https://t.co/hAH43sFSTg
Six-Step Playbook for Risk‑Stratified Lipid‑Lowering Therapy
Reducing cardiovascular risk: a playbook for lipid-lowering pharmacotherapy Risk-stratified targets and a six-step playbook for choosing, combining, and escalating lipid-lowering therapy https://t.co/PcIQNxmivX https://t.co/SzTN9ZAD85
ONC Secures $20M for Huahi's Hexavalent Trispecific
If you're wondering what $ONC got for its $20 m, here's the #AACR25 detail on Huahi's HH160, a symmetrical hexavalent trispecific anti PD-1 x CTLA-4 x VEGF-A MAb https://t.co/Y0jVjTuMMo
Quantum-Designed Drug Hits Nature Biotech Cover, New Pan‑KRAS Inhibitors Available
Our drug from a quantum computer paper made the cover of Nature Biotechnology. It was amazing to hold the physical copy of the journal while visiting our UAE site. We will order a bunch for the office - I love...
Real Drug Development Experience Needed to Validate AI Claims
If you have never gone through even one cycle of the whole drug development process, it is hard for me to believe your AI solution is ‘transformative’ for this process…
Boosting T Helper Cells Could Curb Lifelong Viral Infections
The immune system actively combats lifelong viral infections acquired at birth, but its response is limited by a reduced pool of T helper cells; enhancing these cells may offer new therapeutic strategies. immunology
Nicotinamide Boosts NK Cells, Induces NHL Remissions
Nicotinamide enhances natural killer cell function and yields remissions in patients with non-Hodgkin lymphoma https://t.co/VrC2ertsVd
Living Vessel ATEV Offers New Hope for Dialysis Access
Humacyte’s ATEV could change the game for dialysis patients who run out of fistula options. It’s a living vessel that resists infection and needs fewer repairs. Major unmet need, big potential. Biotech
Scientists, Not Regulators, Block Revolutionary Medicines
Finally, a show exposing the main obstacle to new medicines. Hint, it’s not the FDA: “Throughout history, society hasn’t always appreciated revolutionary scientific findings. For hundreds of years & still today, some of the biggest attackers are fellow scientists.” 🧑🔬🔥👩🔬 https://t.co/h2BpILNV4D
Apple Vision Pro Enables First Spatial-Computing Cataract Surgery
An ophthalmologist in San Diego just performed the first Apple Vision Pro-assisted cataract eye surgery. Dr. Tommy Korn (aka medicine's first "chief spatial computing medical officer") did it as part of a clinical study. Main benefits are easy access to patient info (visual...
FDA Partners with AZN, AMGN to Accelerate AI-Driven Trials
FDA launches effort with $AZN $AMGN to speed up clinical trials, using AI https://t.co/k4LjxnDLmq via @LizzyLaw_
Biotech Hits Jan 2026 High; Bulls Must Curl
Biotech back to the January 2026 high. Bulls need a curl here… or risk getting trapped back in the range. $XBI https://t.co/cfcXch5jD4
RNA‑based Herbicide Kills Resistant Weeds, Leaves Crops Untouched
🟢 GreenLight = no chemical residues on our crops 🌱 The company heard the call to get off of glyphosates and already has more EPA approvals and products in the pipeline than any other new approach. Why does this matter? Herbicide resistant weeds...
Psychedelics May Reverse Epigenetic Roots of Addiction
Epigenetic Mechanisms of Psychedelics in Addiction: Emerging Evidence and Therapeutic Potential these compounds may directly counteract the epigenetic and transcriptional imprints that sustain compulsive substance use https://t.co/GJyHoLPL83
Charting FDA‑Guided Trial Pathways for Merkel Cell Carcinoma
Really enjoyed my fireside chat at MCC4 with Harpreet Singh, MD, the CMO at Precision Medicine, focused on establishing pathways for clinical trials in Merkel cell carcinoma. The physician-scientists in the audience were clearly excited about the prospect of working...
AI Protein Design Advances, Yet Developability Remains Overlooked
Some new protein design competition results from Rio, showing the field keeps tackling harder and harder targets w/ AI methods Might be time to factor in other properties (developability, manufacturability)? https://t.co/h1niVwjnSS
PAI‑1 Deficiency Extends Lifespan via Longer Telomeres
“🔘 Heterozygosity was associated with significantly longer leukocyte telomere length, lower fasting insulin levels, and lower prevalence of diabetes mellitus. 🔘In the extended Amish kindred, carriers of the null SERPINE1 allele had a longer life span. 🔘Our study indicates a causal effect...
Integrated Academic-Community Tumor Board Enhances Precision Medicine
Implementation & Utility of an Integrated Academic-Community #PrecisionMedicine Molecular Tumor Board [MTB] [Jul 5, 2017] @meburkard et al. @JCOPO_ASCO https://t.co/HOWIx826Lm https://t.co/1JmBdW6K5c
Distinguishing Reportable vs Pragmatic Actionability in Precision Medicine
Reportable actionability versus pragmatic actionability: implementing #PrecisionMedicine at three large health systems. @mtmdphd et al. Abstract 6539 #ASCO18 https://t.co/bT29xyztZd https://t.co/tjxR7LC1hH
Molecular Tumor Boards Cut Costs, Reduce Recommendation Discordance
Quantifying the Value of Molecular Tumor Board: Discordance Recommendation Rate & Drug Cost Avoidance [10/20/22] Walters @JimW9200 @antonyruggeri @mullane_michael Hunt, Wilson, Ramczyk, @mtmdphd @JCOPO_ASCO https://t.co/OORXChBGjx #PrecisionMedicine #hpeonc @Aurora_Cancer https://t.co/ZUQXq4npfh
Overcoming Barriers to Community Oncology Precision Medicine
Implementing #PrecisionMedicine Programs and #ClinicalTrials in the Community-Based Oncology: Practice: Barriers and Best Practices - @JLErsek @lorablk @mtmdphd & @EdKimMDLCI #ASCO18 Education Book https://t.co/ahsmfePatk #NCORP
BPL-003
Great piece from @Shea_ARK "AtaiBeckley is advancing BPL-003—an intra-nasal formulation derived from 5-MeO-DMT—in treatment-resistant depression, with positive Phase 2b results supporting a Phase 3 initiation in the second quarter of 2026.[11] With FDA Breakthrough Therapy designation, BPL-003 has the potential...
PurIST Classifier Validated for Tailored Pancreatic Cancer Therapy
Real-World Validation of the Purity Independent Subtyping of Tumors Classifier for Informing Therapy Selection [PurIST @TempusAI] in Pancreatic Ductal Adenocarcinoma [Sep 4, 2025] @stephwen et al. @JCOPO_ASCO https://t.co/R24DErvaB4 #pancsm #PrecisionMedicine https://t.co/KNJHtWovqT
Biliary Cancer Subtypes Show Distinct Immune Signatures
Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures [Jun 8, 2022] @kabir_mody et al. @MarkYarchoan @JCOPO_ASCO https://t.co/IN6UsL5jvN #hpbcsm #PrecisionMedicine https://t.co/p3BzJ82oxA
BRAF Class II/III Mutations Represent Unmet Clinical Need
Real-world clinical genomic analysis of Pts w/ BRAF mutated cancers identifies BRAF class II & III as a population of unmet medical need [3/7/22] Severson etal #ESMO2240P @TempusAI https://t.co/s5PEBEczlv @Annals_Oncology DOI: https://t.co/c3wxWyUuX0 #PrecisionMedicine #caxtx
ASCO Endorses Somatic Genomic Testing for Advanced Cancers
Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: @ASCO Provisional Clinical Opinion [Feb 17, 2022] @CDebyaniPhD et al. @JCO_ASCO https://t.co/hfHUBS3Unx #PrecisionMedicine https://t.co/GwYOMRD1hh
BRAFV600E‑mutated Pediatric Gliofibroma Shows Fleeting Therapy Response
Rare Pediatric Invasive Gliofibroma Has BRAFV600E Mutation and Transiently Responds to Targeted Therapy Before Progressive Clonal Evolution [Mar 27, 2019] @KanevaMD et al. @JCOPO_ASCO https://t.co/oNbfrK7EZr #PrecisionMedicine #btsm https://t.co/V7k9vEiqKm
KRASG12C Mutations Linked to Distinct Immuno‑oncology Biomarkers
Landscape of KRASG12C, Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers [Mar 23, 2022] @SalemGIOncDoc et al. @JCOPO_ASCO https://t.co/iehC82lyA4 #ImmunoOnc #PrecisionMedicine @TempusAI https://t.co/wZzfdnBoXU